Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126121791 | 12612179 | 1 | I | 20160606 | 20160801 | 20160801 | EXP | KR-NORTH CREEK PHARMACEUTICALS LLC-2016VTS00031 | NORTH CREEK PHARMACEUTICALS | KIM Y-J, SOHN CH, RYOO SM, ET AL.. DIFFERENCE OF THE CLINICAL COURSE AND OUTCOME BETWEEN DAPSONE-INDUCED METHEMOGLOBINEMIA AND OTHER TOXIC-AGENT-INDUCED METHEMOGLOBINEMIA. CLIN TOXICOL (DOI: 10.1080/15563650.2016.1178759). 2016 | 0.00 | Y | 0.00000 | 20160801 | OT | KR | KR |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126121791 | 12612179 | 1 | PS | DAPSONE. | DAPSONE | 1 | Oral | U | 204074 |
Indications of drugs used
no results found |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126121791 | 12612179 | HO |
126121791 | 12612179 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126121791 | 12612179 | Brain injury | |
126121791 | 12612179 | Coma | |
126121791 | 12612179 | Haemolysis | |
126121791 | 12612179 | Intentional overdose | |
126121791 | 12612179 | Methaemoglobinaemia | |
126121791 | 12612179 | Multiple organ dysfunction syndrome | |
126121791 | 12612179 | Pneumonia | |
126121791 | 12612179 | Renal failure | |
126121791 | 12612179 | Respiratory failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |